Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Near-future ocean acidification does not alter the lipid content and fatty acid composition of adult Antarctic krill.

Ericson JA, Hellessey N, Kawaguchi S, Nichols PD, Nicol S, Hoem N, Virtue P.

Sci Rep. 2019 Aug 26;9(1):12375. doi: 10.1038/s41598-019-48665-5.

2.

Adult Antarctic krill proves resilient in a simulated high CO2 ocean.

Ericson JA, Hellessey N, Kawaguchi S, Nicol S, Nichols PD, Hoem N, Virtue P.

Commun Biol. 2018 Nov 13;1:190. doi: 10.1038/s42003-018-0195-3. eCollection 2018.

3.

Challenging the claim that intake of krill oil is associated with increased metabolic risk in overweight men.

Hoem N.

Am J Clin Nutr. 2016 Jun;103(6):1557-8. doi: 10.3945/ajcn.116.133017. No abstract available.

PMID:
27251188
4.

Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels.

Berge K, Musa-Veloso K, Harwood M, Hoem N, Burri L.

Nutr Res. 2014 Feb;34(2):126-33. doi: 10.1016/j.nutres.2013.12.003. Epub 2013 Dec 18.

5.

Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men.

Berge K, Piscitelli F, Hoem N, Silvestri C, Meyer I, Banni S, Di Marzo V.

Lipids Health Dis. 2013 May 27;12:78. doi: 10.1186/1476-511X-12-78.

6.

Marine omega-3 phospholipids: metabolism and biological activities.

Burri L, Hoem N, Banni S, Berge K.

Int J Mol Sci. 2012 Nov 21;13(11):15401-19. doi: 10.3390/ijms131115401. Review.

7.

Effects of similar intakes of marine n-3 fatty acids from enriched food products and fish oil on cardiovascular risk markers in healthy human subjects.

Kirkhus B, Lamglait A, Eilertsen KE, Falch E, Haider T, Vik H, Hoem N, Hagve TA, Basu S, Olsen E, Seljeflot I, Nyberg L, Elind E, Ulven SM.

Br J Nutr. 2012 May;107(9):1339-49. doi: 10.1017/S0007114511004508. Epub 2011 Sep 15.

PMID:
21917191
8.

Elucidation of phosphatidylcholine composition in krill oil extracted from Euphausia superba.

Winther B, Hoem N, Berge K, Reubsaet L.

Lipids. 2011 Jan;46(1):25-36. doi: 10.1007/s11745-010-3472-6. Epub 2010 Sep 17.

9.

A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling.

Carlsson KC, van de Schootbrugge M, Eriksen HO, Moberg ER, Karlsson MO, Hoem NO.

Ther Drug Monit. 2009 Feb;31(1):86-94. doi: 10.1097/FTD.0b013e318194767d.

PMID:
19077930
10.

Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis.

Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, Nguyen T, Hsu D, Rao PA, Shapiro B, Gill M.

Antimicrob Agents Chemother. 2005 Dec;49(12):5013-7.

11.

Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.

Beringer P, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, Wong-Beringer A.

Antimicrob Agents Chemother. 2005 Sep;49(9):3676-81.

12.
13.

Analgesic effect of dextromethorphan in neuropathic pain.

Carlsson KC, Hoem NO, Moberg ER, Mathisen LC.

Acta Anaesthesiol Scand. 2004 Mar;48(3):328-36.

PMID:
14982566
14.

Pharmacokinetics in dogs after oral administration of two different forms of ascorbic acid.

Wang S, Berge GE, Hoem NO, Sund RB.

Res Vet Sci. 2001 Aug;71(1):27-32.

PMID:
11666144
15.

Influence of mild hypothermia after hypoxia-ischemia on the pharmacokinetics of gentamicin in newborn pigs.

Satas S, Hoem NO, Melby K, Porter H, Lindgren CG, Whitelaw A, Thoresen M.

Biol Neonate. 2000;77(1):50-7.

PMID:
10658831
16.

Part of prekallikrein removed from human plasma together with IgG--immunoblot experiments and functional tests.

Briseid K, Hoem NO, Johannesen S.

Scand J Clin Lab Invest. 1999 Feb;59(1):55-63.

PMID:
10206098
17.

Contact activation factors in plasma from women on estrogen replacement therapy after ovariohysterectomy.

Fossum S, Hoem NO, Gjønnaess H, Briseid K.

Thromb Res. 1999 Feb 15;93(4):161-70.

PMID:
10064271
18.

Lidocaine pharmacokinetics and toxicity in newborn pigs.

Satas S, Johannessen SI, Hoem NO, Haaland K, Sørensen DR, Thoresen M.

Anesth Analg. 1997 Aug;85(2):306-12.

PMID:
9249105
19.

Significance of IgG for the activity of factor XII measured in human plasma.

Briseid K, Hoem NO, Johannesen S, Vangen AM, Westgaard T.

Scand J Clin Lab Invest. 1996 Dec;56(8):725-34.

PMID:
9034354
20.
21.

Amidolytic assay of factor XI in human plasma--significance of kallikrein for the activity measured.

Briseid K, Hoem NO, Johannesen S, Haug K.

Thromb Res. 1995 May 1;78(3):239-50.

PMID:
7631304
22.

Contact factors in plasma from women on oral contraception--significance of factor XI for the measured activity of factor XII.

Fossum S, Hoem NO, Johannesen S, Korpberget M, Nylund E, Sandem S, Briseid K.

Thromb Res. 1994 Jun 1;74(5):477-85.

PMID:
8085248
24.
25.

Contact activation factors in plasma from pregnant women--increased level of an association between factor XII and kallikrein.

Briseid K, Hoem NO, Johannesen S, Fossum S.

Thromb Res. 1991 Jan 15;61(2):123-33.

PMID:
2020942
26.

A new case of total kininogen deficiency.

Stormorken H, Briseid K, Hellum B, Hoem NO, Johansen HT, Ly B.

Thromb Res. 1990 Dec 15;60(6):457-67.

PMID:
2127962
27.

Functional correlation between kallikrein and factor XII activated in human plasma.

Briseid K, Hoem NO, Johannesen S, Marthinsen K.

Thromb Res. 1990 Mar 15;57(6):945-56.

PMID:
1696402
29.

Rocket immunoassay of high and low molecular weight kininogens in human plasma.

Hoem NO, Johansen HT, Johannesen S, Briseid K.

Adv Exp Med Biol. 1989;247A:337-43.

PMID:
2603799
31.

Effects of intravenous radiographic contrast media on the blood pressure and on factors of the contact activation system in the rat.

Hoem NO, Briseid G, Ekelund S, Salvesen S.

Acta Pharmacol Toxicol (Copenh). 1986 Sep;59(3):189-94.

PMID:
2432754
32.
33.
34.

Reduced cofactor function of human high molecular weight kininogen induced by rat plasma kallikrein.

Hoem NO, Briseid K.

Acta Pharmacol Toxicol (Copenh). 1985 Jul;57(1):47-52.

PMID:
3850711

Supplemental Content

Support Center